Related Articles by Review for PMID: 23129602

Year	Number of Results
1983	1
1992	1
1993	3
2000	1
2002	2
2003	3
2004	2
2005	1
2006	3
2007	3
2008	3
2009	4
2010	3
2011	6
2012	11
2013	25
2014	35
2015	76
2016	85
2017	70
2018	53
2019	26
2020	39
2021	36
2022	33
2023	26
2024	9

1

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.

Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Raal F, et al. Circulation. 2012 Nov 13;126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055. Epub 2012 Nov 5. Circulation. 2012. PMID: 23129602 Clinical Trial.

2

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF. Sahebkar A, et al. Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Clin Ther. 2013. PMID: 23932550 Review.

3

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.

Joseph L, Robinson JG. Joseph L, et al. Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):19-31. doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1. Prog Cardiovasc Dis. 2015. PMID: 25936907 Review.

4

Evolocumab: A Review in Hyperlipidemia.

Keating GM. Keating GM. Am J Cardiovasc Drugs. 2016 Feb;16(1):67-78. doi: 10.1007/s40256-015-0153-0. Am J Cardiovasc Drugs. 2016. PMID: 26643308 Review.

5

PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.

Paton DM. Paton DM. Drugs Today (Barc). 2016 Mar;52(3):183-92. doi: 10.1358/dot.2016.52.3.2440527. Drugs Today (Barc). 2016. PMID: 27186592 Review.

6

An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.

Ling H, Burns TL, Hilleman DE. Ling H, et al. Cardiovasc Ther. 2014 Apr;32(2):82-8. doi: 10.1111/1755-5922.12056. Cardiovasc Ther. 2014. PMID: 24354905 Free article. Review.

7

Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.

Yoon CH, Watson K. Yoon CH, et al. Ann Pharmacother. 2014 Feb;48(2):238-49. doi: 10.1177/1060028013511425. Epub 2013 Nov 6. Ann Pharmacother. 2014. PMID: 24259646 Review.

8

Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.

Okere AN, Serra C. Okere AN, et al. Pharmacotherapy. 2015 Aug;35(8):771-9. doi: 10.1002/phar.1621. Epub 2015 Aug 8. Pharmacotherapy. 2015. PMID: 26256279 Review.

9

PCSK9 antibodies for the treatment of hypercholesterolemia.

Gouni-Berthold I, Berthold HK. Gouni-Berthold I, et al. Nutrients. 2014 Dec 1;6(12):5517-33. doi: 10.3390/nu6125517. Nutrients. 2014. PMID: 25470376 Free PMC article. Review.

10

PCSK9 antibodies: A new class of lipid-lowering drugs.

Gouni-Berthold I. Gouni-Berthold I. Atheroscler Suppl. 2015 May;18:21-7. doi: 10.1016/j.atherosclerosissup.2015.02.003. Atheroscler Suppl. 2015. PMID: 25936300 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

509 results

Results by year